RxDoctor Payments Data

Christina Brash

Family · Oak Hill, WVNPI 1962821736

Payments from drug & device makers

$599in general payments, 2019–2025

Across 28 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$180
  • Novo Nordisk$133
  • Abbott$117
  • Lilly USA, LLC$47
  • Aimmune Therapeutics, Inc.$26
  • Pfizer$19
  • plus $76 from 5 others

What the payments were for

  • Food & beverage$599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$599 in reported general payments places this provider in the 55th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$2,753
Medicare patients
86
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide153$156,753
EliquisApixaban108$141,437
TrulicityDulaglutide78$118,711
JanuviaSitagliptin Phosphate70$96,523
MounjaroTirzepatide83$90,854
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$51,251
TradjentaLinagliptin20$25,638
CreonLipase/Protease/Amylase20$24,488
Breo ElliptaFluticasone/Vilanterol37$22,555
XareltoRivaroxaban16$21,155
LinzessLinaclotide13$20,198
Spiriva HandihalerTiotropium Bromide12$18,002
EntrestoSacubitril/Valsartan15$17,990
BrilintaTicagrelor13$16,966
MyrbetriqMirabegron13$16,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$47$209,565161 claims
Novo NordiskOzempic$133$156,753153 claims
PfizerEliquis$19$141,437108 claims
AbbVieCreon, Linzess$180$44,68633 claims
AstraZenecaBrilinta, Symbicort$14$30,67247 claims
NovartisEntresto$16$17,99015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,507 family providers in West Virginia.

Other family in Oak Hill

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →